Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the distribution of nasal sprays and nasal drops when used.

Detailed Description
-----------------
The purpose of this study is to determine the distribution of nasal sprays and nasal drops when used. The study hypothesizes that nasal drops will reach the frontonasal region more often than nasal sprays.

Official Title
-----------------
Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

Conditions
-----------------
Chronic Sinusitis

Intervention / Treatment
-----------------
* Radiation: Sinus CT Scan
* Drug: Omnipaque 240 Contrast Solution
* Drug: Omnipaque 240 mg I/mL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult able to perform activities of daily living Exclusion Criteria: signs or symptoms of acute or chronic paranasal sinus disease history of sinus surgery symptomatic deviated septum active seasonal allergies allergies to contrast history of nasal polyposis pregnant or breast feeding women neck or back problems that would prevent a subject from kneeling on the floor and crouching over currently taking metformin or amiodarone students or stff under the direct supervision of the investigators cognitive impairment terminal illness

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nasal spray<br>This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses. | Radiation: Sinus CT Scan<br>* Subjects will undergo a Xoran miniCAT scan of their sinuses<br>Drug: Omnipaque 240 Contrast Solution<br>* Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.<br>* Other names: contrast enhancement;|
| Experimental: Nasal drop<br>This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses. | Radiation: Sinus CT Scan<br>* Subjects will undergo a Xoran miniCAT scan of their sinuses<br>Drug: Omnipaque 240 mg I/mL<br>* Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.<br>* Other names: contrast enhancement;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To Measure the Distribution of Nasal Sprays and Drops. | CT scan scored for distribution contrast delivered by nasal spray or drops within subsets in the nasal cavity. The sinonasal cavity was divided into twenty-one subsites on each side of the nasal cavity. The interpreters scored for the presence (1) or absence (0) of contrast from the nasal spray or nasal drops within each subsite. Left and right sides were interpreted separately for a possible total score of 0-42 for each CT scan. | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nasal Spray, Nasal Drop, Intranasal Medication